Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Adherence, persistence and treatment switching in psoriasis.
Santoleri F, Musicco F, Fulgenzio C, Abrate P, Pestrin L, Pasut E, Modesti G, Giannini R, Rosa S, Piccoli M, Mingolla G, Zuzolo E, Gazzola P, Roperti M, Pieri G, Montresor V, Martignoni I, Gambera M, Langella R, Tinari G, Spoltore C, Roberti C, Fabio LD, Grossi L, Guarino F, Vita F, Lasala R, Costantini A. Santoleri F, et al. Among authors: fulgenzio c. Immunotherapy. 2024 Apr 23. doi: 10.2217/imt-2023-0343. Online ahead of print. Immunotherapy. 2024. PMID: 38651935
Effect of Fluoroquinolone Use in Primary Care on the Development and Gradual Decay of Escherichia coli Resistance to Fluoroquinolones: A Matched Case-Control Study.
Kurotschka PK, Fulgenzio C, Da Cas R, Traversa G, Ferrante G, Massidda O, Gágyor I, Aschbacher R, Moser V, Pagani E, Spila Alegiani S, Massari M. Kurotschka PK, et al. Among authors: fulgenzio c. Antibiotics (Basel). 2022 Jun 18;11(6):822. doi: 10.3390/antibiotics11060822. Antibiotics (Basel). 2022. PMID: 35740228 Free PMC article.
ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy.
Santoleri F, Lasala R, Abrate P, Pestrin L, Pasut E, Modesti G, Musicco F, Fulgenzio C, Zuzolo E, Pieri G, Roperti M, Gazzola P, Gambera M, Martignoni I, Montresor V, De Vita F, Guarino F, Grossi L, Di Fabio L, Roberti C, Spoltore C, Tinari G, De Rosa S, Giannini R, Langella R, Mingolla G, Piccoli M, Costantini A. Santoleri F, et al. Among authors: fulgenzio c. Curr Med Res Opin. 2023 Dec;39(12):1729-1735. doi: 10.1080/03007995.2023.2287600. Epub 2023 Dec 15. Curr Med Res Opin. 2023. PMID: 37994874
A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions.
Musicco F, Lasala R, Santoleri F, Costantini A, Abrate P, Carretta MT, Proli EM, Romagnoli A, Petragnani N, Vita F, Zeuli M, Vici P, Sansone M, Pasquantonio M, La Malfa A, Fulgenzio C. Musicco F, et al. Among authors: fulgenzio c. J Oncol Pharm Pract. 2023 Dec;29(8):1806-1815. doi: 10.1177/10781552221117135. Epub 2022 Jul 29. J Oncol Pharm Pract. 2023. PMID: 35903919
A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy.
Musicco F, Fulgenzio C, Malfa A, Jannitti N, Vitiello A, Carpano S, Fusco F, Cappuzzo F, Terrenato I, Sperduti I, Polidori P, Tarantino D, Cerbo LD, Pani M, Isgrò V, Lasala R. Musicco F, et al. Among authors: fulgenzio c. J Oncol Pharm Pract. 2024 Mar 27:10781552241242096. doi: 10.1177/10781552241242096. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38533561 Free article.